169
The Moderna stock continues to follow the bullish trail, after the strong gains reported last Friday on Wall Street, following the news concerning the discovery of the nu variant, or also the South African variant, later renamed Omicron.
The prices jumped by more than 11% in the premarket after flying by 20% in the session on Friday.
Yesterday, Moderna head of medical division Paul Burton said the company could be able to produce a new vaccine against the Omicron variant by early 2022.